NASDAQ:INDP Indaptus Therapeutics Q3 2024 Earnings Report $3.38 +0.12 (+3.74%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$3.42 +0.03 (+0.98%) As of 06/26/2026 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Indaptus Therapeutics EPS ResultsActual EPS-$8.96Consensus EPS -$13.16Beat/MissBeat by +$4.20One Year Ago EPSN/AIndaptus Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIndaptus Therapeutics Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call DateTuesday, November 12, 2024Conference Call Time7:00AM ETUpcoming EarningsIndaptus Therapeutics' Q2 2026 earnings is estimated for Monday, August 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Indaptus Therapeutics Earnings HeadlinesIndaptus Therapeutics (NASDAQ:INDP) Upgraded to Hold at Wall Street ZenJune 27 at 1:24 AM | americanbankingnews.comReviewing United Therapeutics (NASDAQ:UTHR) and Indaptus Therapeutics (NASDAQ:INDP)June 22, 2026 | americanbankingnews.comRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before June 30 could reprice this stock from $2 to $20 or more within a year. | Paradigm Press (Ad)Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. StockholdersJune 17, 2026 | globenewswire.comIndaptus Therapeutics Announces Recent Board and Leadership ChangesJune 5, 2026 | tipranks.comIndaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertaintyJune 4, 2026 | quiverquant.comQSee More Indaptus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email. Email Address About Indaptus TherapeuticsIndaptus Therapeutics (NASDAQ:INDP), is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease. Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors. The company is also exploring applications in antiviral immunotherapies, reflecting the versatility of its platform. By combining advanced engineering techniques with scalable manufacturing processes, Indaptus aims to deliver off-the-shelf therapies to patients with unmet medical needs. Headquartered in the United States, Indaptus collaborates with academic institutions and contract research organizations to advance discovery and clinical translation. Since its inception, the company has established state-of-the-art research and development facilities to support process development, preclinical evaluation, and future clinical manufacturing. Led by a management team with deep experience in cell and gene therapy development, Indaptus is positioned to move its lead programs into early-phase clinical trials and expand its strategic partnerships in the biopharmaceutical industry.View Indaptus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneFabrinet Is Becoming a Quiet Winner in the AI Optics BuildoutMicron’s HBM Surge Could Redefine the AI Growth StoryCarnival's Second Quarter: Is the Stock Still Complicated?Xcel Energy Stock Offers Stability as Electricity Demand BuildsThis Single Factor Is Holding Back Carvana’s Disruptive EdgePaychex Stock Looks Beaten Down, But Not Broken Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
